| pubmed-article:9345340 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9345340 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:9345340 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:9345340 | lifeskim:mentions | umls-concept:C0002475 | lld:lifeskim |
| pubmed-article:9345340 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:9345340 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:9345340 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:9345340 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:9345340 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9345340 | pubmed:dateCreated | 1997-11-19 | lld:pubmed |
| pubmed-article:9345340 | pubmed:abstractText | The combination of cisplatin (CDDP 100 mg/m2 on day 1) and 5-fluorouracil (5-FU 1,000 mg/m2 continuous intravenous (i.v.) infusion days 1-5) is the most widely used chemotherapy regimen for the treatment of advanced head and neck carcinomas, with a response rate of 70-90% but with a survival and a duration of response which are not impressive. Most patients relapse in < or = 2 years and die of cancer. We evaluated the activity of a CDDP (90 mg/m2 on day 1), 5-FU (900 mg/m2/120 h continuous i.v. infusion from day 1), and mitomycin C (MMC 6 mg/m2 on day 1) regimen in advanced or recurrent head and neck squamous cell carcinoma (HNSCC). Fifty-six patients were treated and evaluated for response and toxicity: 5 (9%) complete responses (CR) and 36 (64%) partial responses, (PR) were observed (response rate 73%). The median duration of response was 12 months, and median survival was 15 months. At a median follow-up of 14 months, the estimated overall survival at 1 year was 65%; at 2 years, it was 35%. Grade 3-4 toxicity was noted in 14 patients, mostly hematologic; overall toxicity required a dose-intensity decrease in 20.2% of all cycles. No treatment-related deaths occurred. The regimen showed a good response rate and an encouraging median duration of response with a good tolerability profile. | lld:pubmed |
| pubmed-article:9345340 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9345340 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9345340 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9345340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9345340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9345340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9345340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9345340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9345340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9345340 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9345340 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9345340 | pubmed:issn | 0277-3732 | lld:pubmed |
| pubmed-article:9345340 | pubmed:author | pubmed-author:CarterNN | lld:pubmed |
| pubmed-article:9345340 | pubmed:author | pubmed-author:VigevaniEE | lld:pubmed |
| pubmed-article:9345340 | pubmed:author | pubmed-author:ClocchiattiLL | lld:pubmed |
| pubmed-article:9345340 | pubmed:author | pubmed-author:IonCC | lld:pubmed |
| pubmed-article:9345340 | pubmed:author | pubmed-author:MansuttiMM | lld:pubmed |
| pubmed-article:9345340 | pubmed:author | pubmed-author:SibauA MAM | lld:pubmed |
| pubmed-article:9345340 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9345340 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:9345340 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9345340 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9345340 | pubmed:pagination | 515-8 | lld:pubmed |
| pubmed-article:9345340 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:meshHeading | pubmed-meshheading:9345340-... | lld:pubmed |
| pubmed-article:9345340 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9345340 | pubmed:articleTitle | Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas. | lld:pubmed |
| pubmed-article:9345340 | pubmed:affiliation | Division of Medical Oncology, Azienda Ospedaliera S. Maria della Misericordia, Udine, Italy. | lld:pubmed |
| pubmed-article:9345340 | pubmed:publicationType | Journal Article | lld:pubmed |
